KFDA revises regulations on novel salt preparations

A person who intends to obtain a manufacturing license for novel salt preparations should submit bioequivalence-tested data to the Korea Food and Drug Administration. But in the case of product approval for generic versions of Pfizer's amlodipine, a new applicant should necessarily conduct clinical trials to ensure their safety and efficacy, whereas a latecomer who intends to seek the same prod...